Table 3.
Clinical efficacy of Ad5.SSTR/TK.RGD treatment as noted by RECIST and CA-125 response.
| Dose | Patient ID | Cancer | Best Response by RECIST* | CA-125 | Subsequent treatment | Current Status+ | Survival (months) | |
|---|---|---|---|---|---|---|---|---|
| Pre-treatment | Post-treatment | |||||||
| 1×109 vp/d | 101 | Ovarian | SD | 3006.6 | 3918.0 | Yes | DOD | 20 |
| 102 | Endometrial | SD | 13.8 | 144.0 | Yes | AWD | 29 | |
| 103 | Ovarian | PD | 84.9 | 123.1 | Yes | AWD | 28 | |
| 5×1010 vp/d | 201 | Ovarian | PD | 319.1 | 409.2 | Yes | DOD | 7 |
| 202 | Ovarian | PD | 9.6 | 14.3 | Yes | DOD | 15 | |
| 203 | Ovarian | PD | 337.9 | 354.0 | Yes | DOD | 8 | |
| 1×1012 vp/d | 301 | Endometrial | PD | 25.7 | 78.1 | No | DOD | 1 |
| 302 | Endometrial | SD | 845.7 | 53.8 | No | Alive, NED | 25 | |
| 303 | Ovarian | PD | 274.8 | 277.3 | No | DOD | 4 | |
| 304 | Ovarian | SD | 299.0 | 255.9 | No | Died of other causes | 1 | |
| 305 | Ovarian | PD | 533.0 | 947.5 | Yes | AWD | 16 | |
| 306 | Ovarian | SD | 400.1 | 385.1 | No | DOD | 1 | |
*
SD=Stable Disease, PD=Progressive Disease.
+
DOD=Dead of disease, AWD=Alive with disease, NED=No evidence of disease